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Palisaded neutrophilic and granulomatous dermatitis (PNGD) is an unusual entity with variable clinical
manifestations and histopathological features. It is associated with a variety of immune-mediated
systemic diseases, most commonly in rheumatoid arthritis. We report a 42-year-old female with
a long-standing history of rheumatoid arthritis, presenting with multiple pruritic erythematous papules
and nodules on the lower legs 1 month after beginning treatment with etanercept. Microscopic exam-
ination of a fully developed lesion showed a diffuse dense interstitial lymphohistiocytic inﬁltrate
interspersed with palisaded granulomas consisting of epithelioid histiocytes and multinucleated giant
cells surrounding central zones of degenerated collagen, neutrophils and leukocytoclastic debris. A
diagnosis of PNGD was made on the basis of typical histopathologic features. Withdrawal of etanercept
led to gradual resolution of the skin lesions, with no new skin lesions appearing afterwards. Although the
correlation between the use of tumor necrosis factor-a (TNF-a) antagonists and the development of
PNGD remains controversial and warrants further investigation, PNGD should be considered in the
differential diagnosis of skin eruptions within a setting of anti-TNF-a therapy.
Copyright  2011, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Palisaded neutrophilic and granulomatous dermatitis (PNGD) is
a rare cutaneous manifestation associated with various autoim-
mune diseases. It represents a disease spectrum encompassing
interstitial granulomatous dermatitis (IGD), arthritis and plaques,
rheumatoid papules, cutaneous extravascular necrotizing granu-
loma, Churg-Strauss granuloma and superﬁcial ulcerating rheu-
matoid necrobiosis. Recently, tumor necrosis factor-a (TNF-a)
antagonists have become widely used for the treatment in
a number of autoimmune-mediated inﬂammatory disorders with
favorable effectiveness, particularly against rheumatoid arthritis
(RA), ankylosing spondylitis, psoriatic arthritis and Crohn’s disease.
Although TNF-a antagonists suppress only a speciﬁc area of the
immune system and are considered safe and well tolerated, various
adverse cutaneous reactions have been confronted. In addition to
the formation of leukocytoclastic vasculitis, urticaria, lichenoid
drug eruptions and lupus erythematosus-like eruptions reported
during TNF-a antagonist therapy,1 it has been suggested that
anti-TNF-a therapy is associatedwith the onset of PNGD.2,3 It is well-Long Road, Section 3, Taipei
1197.
ang).
iwanese Dermatological Associatioknown that RA is the most common disease associated with PNGD;
however, the correlation between the use of TNF-a antagonists and
the development of PNGD in patients with RA remains controver-
sial. We report a case of PNGD following treatment with etanercept
for RA, and explore possible causal links.Case presentation
A female (age, 42 years) had a medical history of RA and hepatitis B
since 2007. Her past medications included sulfasalazine 1000 mg,
hydroxychloroquine 400 mg, leﬂunomide 10 mg and entecavir
0.5 mg per day regularly. Due to exacerbated arthralgia, injections
of etanercept were added in June 2009. One month after the
beginning of treatment with etanercept, the patient developed
pruritic skin eruptions starting bilaterally from the lower legs, with
lesions gradually spreading to the trunk and upper limbs
(Figure 1A). An examination revealed multiple scattered erythem-
atous papules and nodules with excoriations distributed symmet-
rically, particularly on the lower legs (Figures 1B and 1C). No
ulceration, discharge, or vesiculation was found. Meanwhile, the
patient showed no signs of fever, loss of body weight or lymph-
adenopathy. Laboratory investigation revealed abnormal liver
function (AST 193 IU/1, ALT 208 IU/1), elevated rheumatoid factorn. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 (A) Multiple scattered erythematous papules and nodules distributed symmetrically on both lower legs, particularly on the extensor aspect. (B) Close-up view of
erythematous papules and nodules with excoriations on right shin. (C) Close-up view of left shin.
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sedimentation rate (ESR; 32 mm/h, normal 0e20 mm/h). Blood cell
count, renal function, C-reactive protein, and IgE were all within
normal limits. The lesions were not alleviated following treatment
with topical corticosteroids and oral antihistamine for 1 month.
Therefore, an incisional skin biopsy was performed.
Pathological sections revealed a diffuse dense interstitial and
perivascular inﬂammatory inﬁltrate throughout the reticular
dermis, composed mainly of histiocytes and lymphocytes. StrikingFigure 2 (A) Diffuse dense interstitial and granulomatous inﬂammatory inﬁltrate through
lomatous inﬂammation consisting of epithelioid histiocytes, multinucleated giant cells and
(C) Prominent palisaded histiocytes surrounding the center of basophilic degenerated coll
cytoclastic debris (H&E stain, magniﬁcation 200).palisaded granulomatous inﬂammation comprised epithelioid
histiocytes, multinucleated giant cells and large numbers of
neutrophils within the mid-dermis were found (Figure 2A). Prom-
inent palisaded histiocytes surrounded the center of basophilic
degenerated collagen (piecemeal fragmentation) and leukocyto-
clastic debris (Figures 2B and 2C). Swollen endothelial cells, ﬁbri-
noid degeneration of vessel walls and erythrocytes extravasation
were also noted. Neither dermal mucin nor leukocytoclastic
vasculitis was found. Subcutaneous tissue remained intact. Theout the reticular dermis (H&E stain, magniﬁcation 40). (B) Striking palisaded granu-
large numbers of neutrophils within the mid-dermis (H&E stain, magniﬁcation 100).
agen, numerous neutrophils with a variable number of eosinophils, ﬁbrin and leuko-
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annulare, rheumatoid neutrophilic dermatitis, interstitial granulo-
matous drug reaction, mycobacterial infection and deep fungal
infection. PAS staining and acid-fast staining of the skin biopsy
demonstrated no microorganisms. Further investigations of
a polymerase chain reaction for Mycobacterium tuberculosis or
nontuberculous mycobacteria provided negative results (Figure 3).
Therefore, a diagnosis of PNGD was made.
Following the skin biopsy, etanercept treatment was immedi-
ately withdrawn. During the 4 months follow-up, only topical
corticosteroids and oral antihistamines were prescribed. The skin
eruption gradually resolved with residual post-inﬂammatory
hyperpigmentation diminishing within 4 months following the
discontinuation of treatment with etanercept (Figure 4A). The
numbers of erythematous papules on the lower legs decreased and
pruritus was improved (Figures 4B and 4C). The patient refused to
resume treatment with etanercept thereafter, and no similar skin
lesions were reported during the follow-up period.
Discussion
This report of PNGD occurring 1 month after beginning treatment
with TNF-a inhibitor in a patient with RA is of considerable
importance. The mechanism behind PNGD remains poorly under-
stood, and the relationship between PNGD and the use of TNF-a
antagonists has not been well established. A number of recent
studies have investigated this correlation. Bremner et al reported
on three patients with RA receiving anti-TNF-a therapy developing
PNGD.2 They suggested that the only common link was RA.
However, Deng et al described ﬁve patients developing PNGD
following the initiation of four different anti-TNF-a therapies
(inﬂiximab, etanercept, adalimumab and lenalidomide).3 Of the
ﬁve patients, three had underlying RA. In addition to RA, one
patient had psoriatic arthritis and the other two patients had
multiple myeloma. Rashes developed within 3 months following
initiation of TNF-a inhibitors in three of the patients. The eruptions
cleared in three of the patients and improved in one patient within
2 months following discontinuation of the TNF-a inhibitors. The
skin lesions persisted in one patient who continued receiving the
TNF-a inhibitor. Deng et al inferred that TNF-a antagonists
enhanced the likelihood of developing PNGD in patients with RA
who also suffered from granulomatous diathesis. In our patient, we
observed a close association between the development of skinFigure 3 The polymerase chain reaction for Mycobacterium tuberculosis and non-
tuberculous mycobacteria were both negative. (Abbreviations: B, blank; N, negative
control; P, positive control; S, specimen; MM, molecular markers).lesions and the initiation of treatment with TNF-a inhibitor, as
described by Deng. Our patient, who had a long-standing history of
RA, did not show evidence of erythematous papules until 1 month
after initiating the use of etanercept. She had severe polyarthralgia
with elevated RF and ESR about 3 years prior, up to 88.6 IU/ml and
50 mm/h, respectively; however, no PNGD lesions were encoun-
tered at that time. The skin eruptions persisted for 5 months during
the period of etanercept therapy despite treatment with topical
corticosteroids. In addition, gradual resolution of skin lesions was
observed within 4 months following discontinuing treatment of
TNF-a inhibitor. Etanercept was not re-administrated and the
patient did not develop similar new skin lesion afterwards. The
time correlation of the lesions with the initiation of etanercept
supports the presumption that the TNF-a inhibitor may have
played a role in this patient developing PNGD. Spontaneous reso-
lution over a period of months to years has been reported in
a number of patients presenting with PNGD. Nonetheless, rapid
resolution of skin lesions in the patient in this study after dis-
continuing use of etanercept made this unlikely.
The mechanism behind PNGD remains unclear. In 1983, Finan
andWinkelmann observed IgM and C3 in small vessels using direct
immunoﬂuorescent examination of skin lesions resulting from
PNGD.4 They presumed that the cutaneous lesions were the result
of immune complexes generated by underlying systemic diseases.
These lesions tended to occur in patients suffering from more
severe diseases and were correlated with high titers of anti-DNA
antibodies, antinuclear antibodies (ANA) and RF.5,6 It is now
believed that the deposition of immune complexes in dermal
vessels activates the complement and neutrophils, leading to
degeneration of ischemia and collagen, followed by granulomatous
reaction to this damaged collagen.7 The exact mechanism by which
the TNF-a antagonist is involved in the promotion of PNGD has not
been conﬁrmed. The development of autoimmunity and ﬂares of
vasculitis are well-known concerns with all TNF-a inhibitors.8
Etanercept is a fully soluble human TNF receptor fusion protein
and, although it does not cause antibody-dependent cytotoxicity or
trigger T-cell apoptosis like inﬂiximab, we assumed that it alters the
antigenicity of dermal collagen and elicits an immune response. It
may also cause other autoantibodies to bind to RF, IgM/C3 or a pre-
formed immune complex to reach a critical size precipitating in the
blood vessels and causing vascular injury through type III immune
complex reaction. After all, the development of PNGDwas triggered
in our patient following the initiation of treatment with etanercept.
Among the TNF-a antagonists, monoclonal antibodies to TNF-a,
such as inﬂiximab and adalimumab, were considered better able to
break down granuloma than etanercept. Etanercept binds primarily
to soluble TNF, whereas inﬂiximab binds to both soluble and
membrane-bound TNF and is able to ﬁx complement and induce
cell lysis and apoptosis of cells expressing membrane-bound
TNF.9,10 Etanercept has not demonstrated clinical beneﬁts in
Wegener’s granulomatosis,11 Crohn’s disease12 or sarcoidosis.13 It
leaves TNFRp75-mediated signaling at least partially intact, which
would explain why etanercept did not completely impair the
formation of palisaded neutrophilic granluoma in our patient.
PNGD is an unusual cutaneous condition found in patients with
a variety of immune-mediated systemic diseases, most commonly
associated with RA. Consistent with its association with immune-
mediated diseases, PNGD has also been diagnosed in conjunction
with systemic lupus erythematosus, Wegener’s granulomatosis,
vasculitis, lymphoproliferative malignancies, Behçet’s disease,
adult-onset Still’s disease and limited systemic sclerosis.14 It was
ﬁrst described by Dykman et al in 1965 in patients with RA devel-
oping indurated linear subcutaneous bands on the lateral aspect of
the trunk.15 In recent years, various names have been proposed to
designate the same entity and in 1994, Chu et al proposed the
Figure 4 (A) The number of erythematous papules was decreased 4 months after skin biopsy and pruritus was also improved. Skin eruption gradually resolved with residual post-
inﬂammatory hyperpigmentation. (B) Close-up view of resolved erythematous papules and nodules on right shin. (C) Close-up view of left shin.
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vascular disease to unify the variety of names given to these
conditions.7 The clinical manifestations of PNGD are highly diverse,
including tender skin-colored erythematous papules with central
crusts and umbilication,7 asymptomatic or pruritic erythematous-
to-violaceous annular papules and plaques, and indurated linear
bands. Linear subcutaneous indurated cordlike bands, the so-called
rope sign, was ﬁrst described by Ackerman in 1993 and considered
pathognomonic of IGD.16 The polymorphous cutaneous eruption is
characterized by symmetrical distribution predominantly on the
trunk and extensor extremities, especially with the upper limbs, as
described by Hantash et al.14 The appearance of these lesions often
coincides with a worsening of the underlying systemic disease.
Chu proposed that, histopathologically, PNGD displays a spec-
trum of various characteristics dependent upon the duration of the
lesions. At different stages, the histologic ﬁndings of PNGD vary
from diffuse interstitial inﬂammation composed of lymphohistio-
cytes, eosinophils and little neutrophils to palisading granuloma
surrounded by dense histiocytic and neutrophilic inﬁltrates with
central degenerated collagen and leukocytoclastic debris. Mucin is
usually scant or absent. In our patient, the histopathologic
appearance displayed a fully developed lesion showing palisaded
granulomas surrounding areas of degenerated collagen, numerous
neutrophils, nuclear dust and ﬁbrin. Leukocytoclastic vasculitis
was not a feature at this stage, although vasculopathy presented
with ﬁbrinoid degeneration and plump endothelial cells. The
main histopathological differential diagnoses included granuloma
annulare, rheumatoid neutrophilic dermatitis and interstitial
granulomatous drug reaction. In granuloma annulare, a palisaded
granuloma, necrobiosis and multinucleated giant cells are
frequently observed. However, the neutrophils and eosinophils are
usually scant or absent and the deposition of dermal mucin is
abundant.17 In our patient, the absence of dermal mucin, deeply
basophilic degenerated collagen in the center of histiocytic pali-
saded granuloma and numerous neutrophilic inﬁltrates were
distinguishing features of PNGD. Rheumatoid neutrophilic derma-
titis is characterized by heavy dermal inﬁltrates of neutrophils
with variable degrees of leukocytoclasis without palisaded necro-
biotic granuloma,18 which is unlike the palisaded neutrophilic
granulomatous inﬂammation in our case. The histopathologic
features of interstitial granulomatous drug reaction are character-
ized by changes in the vacuolar interface and often byepidermotropism of the lymphocyte, in addition to diffuse lym-
phohistiocytic inﬁltrate and piecemeal fragmentation of collagen.
The absence of neutrophils is a cardinal feature differentiating
PNGD.19 Other forms of palisaded granulomatous dermatitis,
including Churg-Strauss disease and Wegener’s granulomatosis,
should also be considered. Churg-Strauss disease typically reveals
abundant eosinophils in the centers of granulomas. In Wegener’s
granulomatosis, there are often many foci of active vasculitis
concurrent with palisaded extravascular granulomas. Furthermore,
it is well known that patients receiving anti-TNF-a therapy face
a signiﬁcant increase in the risk of infection from Mycobacterium
tuberculosis. Therefore, tuberculosis should be considered (with
caution) in the differential diagnosis.
The clinical course of PNGD tends to be self-limiting. Most cases
resolve spontaneously, while others may persist for several months
or years. In our patient, signiﬁcant clinical improvement was
observed following the withdrawal of etanercept. Several treat-
ments have shown variable improvements in PNGD, including
topical corticosteroids, low-dose prednisolone, dapsone,2 colchi-
cine, cyclosporin, cyclophosphamide20 and hydroxychloroquine.Conclusion
In conclusion, we report a case of PNGD developing after the
initiation of treatment with etanercept, subsequently subsiding
following the discontinuation of treatment. PNGD should be
considered in the differential diagnosis of skin eruptions in the
setting of anti-TNF-a therapy. The TNF-a antagonist could play
a role in triggering PNGD via autoimmunity in patients with
immune-mediated diseases. Further studies are indicated to clarify
the association and identify the precise mechanism between TNF-a
inhibitors and PNGD.References
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